Navigation Links
Telescope Embedded in Spectacle Lens Promises to Make Driving Easier for Visually Impaired
Date:7/24/2008

>While these bioptic telescopes are useful and helpful, many potential users have resisted them because of their strange appearance, and because the magnified view through the telescope is narrow.

In the newer glasses, Peli and his co-inventor Dr. Vargas-Martin from the University of Murcia, Spain, designed a wide-field telescope made of straight and curved mirrors built completely within the spectacle lens,

The Journal of Biomedical Optics article describes the process that Peli and his team went through as they created and tested various prototypes of telescopes leading to the design that would be most effective and comfortable for patients with low vision. They started with a telescope made with mirrors and lenses to prove the image shifting principle. To embed the whole telescope inside the spectacle lens they had to obtain the magnifying power from curved mirrors instead of lenses, as mirrors maintain their power when embedded inside the spectacle lens, while the lenses lose their power when not in the air. Regular spherical mirrors can not be tilted without loss of focus, so they constructed a version made with tilted parabolic mirrors. The latter worked well and was in focus, but the images were distorted enough due to the parabolic shape to cause a disturbing effect during head movements. The latest design they constructed is based on spherical and flat mirrors with the flat mirrors implemented as tilted beam splitters that use polarization to reduce light loss.

Says Peli, "The short height of the actual magnifier, its position, and inclusion of a small tilt of the last flat mirror (the one closest to the user's eye), enables the wearer to simultaneously view the magnified field above the unmagnified view of the uninterrupted horizontal field.

Not only will the new glasses improve the cosmetics and usefulness of this type of device, the in-the-lens design will make it possible to mass-produce the telescopic magnifier as a standard
'/>"/>

SOURCE Schepens Eye Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. James Webb Space Telescope marks successful completion
2. Amazing minaturized SIDECAR drives Webb telescopes signal
3. SkyeTek to Present Webinar on Transforming the Management of Medical Devices & Supplies with Embedded RFID
4. Nano-sized electronic circuit promises bright view of early universe
5. Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016
6. Contract Services for Big Pharma and Biotechs Driving Growth and Innovation from Discovery to Clinical Trials
7. Actress and Mom Lori Loughlin Raises Awareness About the Potential Dangers of Drowsy Driving During Allergy Season
8. Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value
9. Decision Biomarkers Launches System for Faster, Easier Quantification of Protein Biomarkers
10. Safer, easier system for remote explosive detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... the development and commercialization of a once-daily, oral therapy ... today announced financial results for the period ended June ... , Reported cash and cash equivalents totaling $37.4 ... December 31, 2013.  , Reported a net loss ...
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... in China , today announced that it ... ended June 30, 2014, after market close on Thursday, August ... prior to the market opening on Friday, August 15, 2014, ... p.m. China Standard Time) to review the Company,s financial results ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... -- ECC West Africa, LLC (ECC) signed a contract in ... Hospital (UCH) Ibadan Board of Management for the first ... and operate and maintain a new, state-of-the-art Cancer Institute ... first of the 4-phase project, ECC will conduct feasibility ... Ibadan intends to finance and develop the Cancer Institute ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... LAFAYETTE, Ind. - Researchers are creating a system that ... reducing a car,s fuel consumption. The effort is ... National Science Foundation and the U.S. Department of Energy. ... which is developing a prototype using thermoelectric generators, or ...
... 2010 Crescent Healthcare today announced a planned expansion ... a lease to open an infusion pharmacy in Totowa, ... services to current patients in Massachusetts, Maryland, New York, ... Rhode Island. In addition to supporting ...
... Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results ...
Cached Biology Technology:Technology uses auto exhaust heat to create electricity, boost mileage 2Technology uses auto exhaust heat to create electricity, boost mileage 3Crescent Healthcare Expands East Coast Presence 2Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 2Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 3Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 4Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 5Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 6Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 7Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 8Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 9Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 10
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... , Washington, D.C. (October 5, 2010) -- The explosion ... such as cell and smart phones, Bluetooth hands-free units, ... from the development of a wide variety of integrated ... on which the communication is based. Continuing ...
... nanotubes -- long, hollow cylinders of carbon billionths of ... in nanotechnology, optics, electronics, and many other fields. The ... scientists as yet have little control over that structure, ... growth -- of the nanotubes. In fact, says chemical ...
... A research team from the University of British Columbia and ... Hospital has identified the role of a type of T ... treatment options for young patients. Also known as juvenile ... children and young adults. In patients with type 1 diabetes, ...
Cached Biology News:The effects of hydrogen on growing carbon nanotubes 2
EZ-Tn5™ Transposase is designed for use with our pMOD™ series of vectors as well as any EZ-Tn5™ transposon system....
... PBL's bioassays for interferons are cytopathic effect ... assays. Sample types include; tissue culture supernatents; ... In these assays, one unit is defined as ... reduce the cytopathic effect of viral infection by ...
HyPro 100, includes 5 x HyPro20 and HyPro Cabinet. 100 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
Biology Products: